We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Pfizer
PFE
$158B
| $91.5M | 0.13% |
3,801,302
+3,203,088
| +535% | +$83.8M |
|
152
PG&E
PCG
$31.3B
| $91.5M | 0.13% |
5,437,700
+1,320,700
| +32% | +$22.2M |
|
153
Insmed
INSM
$28.1B
| $90.6M | 0.13% |
850,000
-50,000
| -6% | -$6.05M |
|
154
Prologis
PLD
$129B
| $89.5M | 0.13% |
660,929
+32,599
| +5% | +$4.62M |
|
155
IDEX
IEX
$16.6B
| $89.4M | 0.13% |
393,913
+327,127
| +490% | +$69.2M |
|
156
Jabil
JBL
$32.6B
| $89.2M | 0.13% |
231,438
+25,547
| +12% | +$8.82M |
|
157
Veralto
VLTO
$23.1B
| $89.2M | 0.13% |
1,005,857
+784,290
| +354% | +$68.1M |
|
158
Newmont
NEM
$136B
| $88.9M | 0.12% |
951,500
+113,900
| +14% | +$12.4M |
|
159
Cadence Design Systems
CDNS
$78.4B
| $88.5M | 0.12% |
235,800
+2,000
| +0.9% | +$701K |
|
|
BNY
160
Bank of New York Mellon
BNY
$110B
| $88.5M | 0.12% |
611,716
-4,800
| -0.8% | -$656K |
|
161
Black Hills Corp
BKH
$5.55B
| $88.2M | 0.12% |
1,185,024
-884,803
| -43% | -$65.2M |
|
162
Danaher
DHR
$144B
| $86.2M | 0.12% |
452,595
+76,568
| +20% | +$13.9M |
|
163
Digital Realty Trust
DLR
$70.1B
| $86.1M | 0.12% |
479,400
+20,100
| +4% | +$3.85M |
|
164
ServiceNow
NOW
$136B
| $85.8M | 0.12% |
864,200
-12,900
| -1% | -$1.28M |
|
165
Mondelez International
MDLZ
$79.7B
| $85.3M | 0.12% |
1,474,097
-359,200
| -20% | -$21.6M |
|
|
EA
166
DELISTED
Electronic Arts
EA
| $85.2M | 0.12% |
415,327
-430,081
| -51% | -$87.1M |
|
|
EXE
167
Expand Energy Corp
EXE
$22.4B
| $85.1M | 0.12% |
933,200
+224,800
| +32% | +$21.4M |
|
168
BorgWarner
BWA
$13.3B
| $84.7M | 0.12% |
1,275,000
+775,000
| +155% | +$49.1M |
|
169
Hilton Worldwide
HLT
$69.1B
| $84.6M | 0.12% |
255,900
+250,000
| +4,237% | +$82.2M |
|
170
Sempra
SRE
$55.6B
| $84.1M | 0.12% |
907,570
-638,600
| -41% | -$59.4M |
|
171
Starbucks
SBUX
$114B
| $84.1M | 0.12% |
822,709
+22,100
| +3% | +$2.23M |
|
172
Spire
SR
$4.82B
| $84.1M | 0.12% |
1,076,440
-125,000
| -10% | -$10.7M |
|
173
US Bancorp
USB
$96.8B
| $83.6M | 0.12% |
1,383,400
+149,097
| +12% | +$8.35M |
|
174
Humana
HUM
$48B
| $83.5M | 0.12% |
+210,120
| New | +$59.8M |
|
175
Hubbell
HUBB
$24B
| $82.9M | 0.12% |
158,480
-58,087
| -27% | -$29.3M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.